Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Recurrence × Lapatinib × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 29 Neoplasm Metastasis 6 Neoplasms 4 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Ovarian Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Squamous Cell 2 Breast Neoplasms, Male 2 Skin Neoplasms 1 Recurrence 1 Pancreatic Neoplasms 1 Metastatic Breast Cancer With Intracranial Metastases 1 Melanoma 1 Inflammatory Breast Neoplasms 1 Her2 Positive Metastatic Breast Cancer 1 Head and Neck Neoplasms 1 HER2 Positive Esophagogastric Cancer 1 GastroEsophageal Cancer 1 Esophageal Squamous Cell Carcinoma 1 Diarrhea 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma, Ductal, Breast 1 Carcinoma 1 Breast Diseases 1 Brain Neoplasms 1 Advanced Solid Tumors 1

Interventions

Cyclophosphamide 21 Dexamethasone 19 Rituximab 16 Cytarabine 16 fludarabine 10 Methotrexate 10 Gemcitabine 10 Bortezomib 10 Lenalidomide 9 Filgrastim 9 Etoposide 8 pembrolizumab 7 Vincristine 7 Paclitaxel 7 Cyclosporine 7 carfilzomib 6 Topotecan 6 Temozolomide 6 Docetaxel 6 Calcium Dobesilate 6 Antilymphocyte Serum 6 pomalidomide 5 fludarabine phosphate 5 Radiotherapy 5 Peripheral Blood Stem Cell Transplantation 5 Pemetrexed 5 Mitoxantrone 5 Granulocyte Colony-Stimulating Factor 5 Doxorubicin 5 Azacitidine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00888810 2009-04-28

TOPO-LAPA

Centre Francois Baclesse

Phase 2 Terminated

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡